Skip to main content
Contact Us
Subscribe
E-Edition
27°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Innate Pharma S.A. ADR
(NQ:
IPHA
)
1.450
UNCHANGED
Streaming Delayed Price
Updated: 3:53 PM EST, Dec 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Innate Pharma S.A. ADR
< Previous
1
2
3
4
5
6
7
8
Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
October 05, 2023
Via
Benzinga
Regulatory Hurdle For Innate Pharma's Blood Cancer Studies
October 05, 2023
The FDA has placed a clinical hold on Innate Pharma SA's (NASDAQ: IPHA) lacutamab Investigational New Drug (IND), leading to a pause in new patient enrollment in ongoing lacutamab trials IPH4102-201...
Via
Benzinga
Exposures
Product Safety
Innate Pharma Provides Update on Lacutamab Clinical Program
October 05, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023
September 22, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Reports First Half 2023 Financial Results and Business Update
September 14, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update
August 29, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Participate in Upcoming Investor Conference
August 10, 2023
From
Innate Pharma SA
Via
Business Wire
First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
July 11, 2023
From
Innate Pharma SA
Via
Business Wire
Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023
July 07, 2023
From
Innate Pharma SA
Via
Business Wire
First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
June 26, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria
June 16, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma
June 12, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress
June 10, 2023
From
Innate Pharma SA
Via
Business Wire
Why Shares of Innate Pharma Jumped Thursday
June 08, 2023
The company's collaboration agreement with Sanofi could soon pay off.
Via
The Motley Fool
SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies
June 08, 2023
From
Innate Pharma SA
Via
Business Wire
Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023
June 07, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML
May 26, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Participate in Upcoming Investor Conferences
May 23, 2023
From
Innate Pharma SA
Via
Business Wire
Outcome of Innate Pharma’s 2023 Annual General Meeting
May 12, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Reports First Quarter 2023 Financial Results and Business Update
May 10, 2023
From
Innate Pharma SA
Via
Business Wire
Number of shares and voting rights of Innate Pharma as of May 1, 2023
May 09, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Conference Call and Webcast for Q1 Business Update
May 03, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting
May 03, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Establishes a New At-The-Market (“ATM”) Program on Nasdaq
April 26, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Participate in Upcoming Investor Conference
April 21, 2023
From
Innate Pharma SA
Via
Business Wire
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
April 19, 2023
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...
Via
Benzinga
Number of Shares and Voting Rights of Innate Pharma as of April 1, 2023
April 18, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 12, 2023
April 07, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Files Its 2022 Universal Registration Document (Document d’enregistrement universel) and 2022 Annual Report on Form 20-F
April 06, 2023
From
Innate Pharma SA
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 03, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.